

UTAH MEDICAL PRODUCTS INC  
Form 8-K  
October 30, 2018

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): October 30, 2018

UTAH MEDICAL PRODUCTS, INC.  
(Exact name of registrant as specified in its charter)

|   |  |  |
|---|--|--|
| <u>Utah</u><br>(State or other jurisdiction of incorporation or organization) | <u>000-12575</u><br>(Commission File Number) | <u>87-0342734</u><br>(IRS Employer Identification No.) |
|---|--|--|

|   |                            |
|---|----------------------------|
| 7043 South 300 West<br><u>Midvale, Utah</u><br>(Address of principal executive offices) | <u>84047</u><br>(Zip code) |
|---|----------------------------|

Registrant's telephone number, including area code: Phone: (801) 566-1200

n/a  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).

Emerging growth company

Edgar Filing: UTAH MEDICAL PRODUCTS INC - Form 8-K

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

---

ITEM 8.01—OTHER EVENTS

On October 30, 2018, Utah Medical Products, Inc. announced that it is increasing its regular quarterly cash dividend. A dividend of \$.275 per share is payable on January 3, 2019 to shareholders of record at the close of business on December 14, 2018. A copy of the press release is attached hereto as Exhibit 99.1

ITEM 9.01—FINANCIAL STATEMENTS AND EXHIBITS

The following is filed as an exhibit to this report:

| Exhibit<br>Number* | Title of Document  | Location       |
|--------------------|--|----------------|
| Item 99.1          | Press release issued October 30, 2018: Utah Medical Products Inc. Increases Quarterly Dividend | This<br>filing |

---

\* All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

UTAH MEDICAL PRODUCTS, INC.

Dated: October 30, 2018 By: /s/ Kevin L. Cornwell  
Kevin L. Cornwell, Chief Executive Officer